Skip to main content
. 2021 Oct 4;9(10):e002505. doi: 10.1136/jitc-2021-002505

Figure 1.

Figure 1

Schematics of the phase I/II OPERA trial. A window of opportunity, during which patients reviewed NOX-A12 (olaptesed pegol) as a monotherapy, was followed by combined NOX-A12 and pembrolizumab therapy until progression or unacceptable toxicity. SCR, screening.